Molecular Formula：
C49H66N10O10S2
Relative Molecular Mass：
1019.26 g/mol
CAS-Number：
83150-76-9 (net), 79517-01-4 (acetate)
Long-term Storage：
-20 ± 5°C
Synonym：
SMS 201-995
Sequence：
H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol acetate salt (Disulfide bond)
Fields of Application：
Acromegaly Carcinoid syndrome VIPomas
Active Substance：
Octreotide Acetate is a longer acting synthetic octapeptide analog of naturally occurring somatostatin. Octreotide Acetate inhibits the secretion of gastro-entero-pancreatic peptide hormones and the release of growth hormone. Octreotide reduces gastrointestinal motility and inhibits contraction of the
gall bladder.
Company Profile:
company name:Shenzhen JYMed Technology Co.,Ltd.
Year Established:2009
Capital: 89.5 Million RMB
Main product: Oxytocin Acetate,Vasopressin Acetate,Desmopressin Acetate,Terlipressin acetate, Caspofungin acetate, Micafungin sodium, Eptifibatide acetate, Bivalirudin TFA, Deslorelin Acetate,Glucagon Acetate,Histrelin Acetate,Liraglutide Acetate,Linaclotide Aceteate ,Degarelix Acetate,Buserelin Acetate,Cetrorelix Acetate,Goserelin
Acetate, Argireline Acetate, Metrixyl Acetate,Snap-8,.....
We strive for continuing innovations in new peptide synthesis technology and process optimization, and our technical team have over decade of experience in peptide synthesis.JYM has successfully submitted a lot
of ANDA peptide APIs and formulated products with CFDA and have over fourty patents approved.
Our peptide plant is located in Nanjing, Jiangsu province and it has set up a facility of 30,000 square meters in compliance with cGMP guideline. The manufacture facility has been audited and inspected by both domestic and international clients.
With its excellent quality, most competitive price and strong technical support, JYM not only has gained recognitions for its products from Research organizations and Pharmaceutical industries, but also become one of the most reliable suppliers of peptides in China,. JYM is dedicated to be one of the world’s leading peptide provider in the near future.